-The Economic Times Nazia is 10 years old. But, according to a claim filed by Chhattisgarh-based Shaheed Hospital with the Rashtriya Swasthya Bima Yojna (RSBY), she has delivered a baby after a caesarean operation. Mukul (name changed) is only 7. But Agarwal Hospital, Raipur, has made a claim for removing cataract from his eyes. A large number of similar implausible claims, being made by private hospitals enrolled to treat poor patients under...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

-The Times of India Medicines in India may not be sold under brand names in the near future. In its biggest move to push generic drugs and do away with brand names, the Union health ministry has ordered states to stop issuing licence for the manufacture or sale of drugs on the basis of their brand name. All pharmaceutical firms applying for licence to market or manufacture fixed dose combination (FDC) drugs will...

-The Indian Express The government’s proposal to price-control certain drugs will create more problems than it will solve From clothes to cars, prices of consumer products the world over are determined taking into account input costs, margins and competition, popularly called the cost-based pricing system. Departing from this sound, fair, tried and tested principle of commerce, the government’s new drug pricing policy, approved by the Group of Ministers headed by Sharad Pawar,...

-Live Mint The first in a two-part series examining the opaque world of clinical trials in India  A hospital in Indore has been able to get away with unethical medical trials in which 32 people have died over five years, according to the state government. This despite several investigations, a state government ban and Supreme Court strictures—a classic example of the lawless nature of the clinical trial business in India.   Lata Mehra, who...